About us

Perceiv is an AI-based digital biomarkers company specializing in the field of precision medicine. We are dedicated to help improving and saving patient lives through more efficient, accurate, subject targeting, and objective prognosis through advanced machine learning algorithms.

Diseases are more complex than they appear resulting in problems when finding the right population to treat and demonstrate treatment efficacy. We help pharmaceutical companies improve their chances of success by identifying the right subjects for their clinical trials using our AI-driven precision medicine platform. We specialize in the identification of subpopulations of interest in heterogeneous data and complex diseases.

Perceiv is currently developing applications for Alzheimer's disease and CNS-related indications.

Ingest structured and unstructured data

Our proprietary platform enables us to ingest various types of data to better characterize individuals (imaging, genetic, phenotypic and clinical variables).

High precision targeting

Identify with very high precision groups of subjects in heterogeneous populations.

Deliver actionable insights

Improve treatment success by appropriate subject selection for clinical trials.

Our expertise

Clinical trial optimization

Reduce clinical trial cost using precision enrollment of patients.

Predictive analytics

Prognostic and diagnostic based on clinical data.


Treatment response prediction

Improve treatment outcome by appropriate targeting of individuals.

Digital biomarkers / Companion diagnostic

Combine multimodal biomarkers using our proprietary platform.

Precision medicine platform



Clinical trials - Alzheimer's disease

Cognitive decline enrichment

Predict future risk of cognitive decline

We provide high precision digital biomarkers of the progression to Alzheimer's dementia at a prodromal stage. Those tools are aimed at population enrichment for clinical trials in Alzheimer's disease and carry the potential to be a cost-saving alternative to the current enrolment strategy as well as maximizing our ability to detect the effectiveness of drugs.

Clinical trials - Alzheimer's disease

Amyloid-beta enrichment

Predict Amyloid-Beta+ subjects using broadly available modalities

We provide a pre-screening strategy for amyloid-beta positive subjects using broadly available modalities before a amyloid PET scan.

Management Team

Christian Dansereau, Ph.D.

CEO & Founder

Dr. Dansereau has over a decade of experience doing machine learning research applied to neuroimaging and medical data. Ph.D. in Computer Science from University of Montreal. Master in Biomedical Engineering from McGill University. Bachelor degree in Electrical Engineering.

César Laurent, Ph.D.(c)

CTO & Founder

Deep Learning researcher from MILA supervised by Pascal Vincent (Facebook) and Yoshua Bengio. Extensive experience with medical data.

Angela Tam, Ph.D.

Scientist & Clinical lead

Postdoctoral fellow at the National University of Singapore. Expertise in multimodal imaging of neurological diseases and psychiatric disorders.


Serge Gauthier, MD, FRCPC

Director of the Alzheimer’s Disease Research Unit at McGill University, Montreal, Canada. Professor of Neurology & Neurosurgery, Psychiatry and Medicine at McGill University, Montreal, Canada. Member, Douglas Mental Health University Institute’s Research Center. Membre Associé, Institut Universitaire de Gériatrie, Université de Montréal.

Robert Amyot, MD

Cardiologist, former president of CAE healthcare, professor of medicine and well-published researcher. Accomplished executive and board member of The Royal College International. Simulation Hall of Fame inductee (2018).

Manon Boisclair, M.Sc., MBA

Executive with 20+ years of diversified international Medical Affairs experience at Merck, Novartis, Celgene now BMS and Intercept Pharma. Extensive medical-marketing experience across therapeutic areas including oncology, cardiology, liver and rare diseases with several blockbusters and pipeline compounds in pre/post-launch initiatives.

Pierre Bellec, Ph.D.

Scientific director of the functional imaging unit. Researcher at the CRIUGM, Computer Science and operations research, University of Montreal. Co-lead of the biomarker team of the Canadian Consortium on Neurodegeneration in Aging (CCNA).

Marc Cantillon, MD

Chief Medical Officer at Shanghai Green Valley Pharmaceutical, Founding member and former Executive Dir, Critical Path Institute Coalition Against Major Diseases (CAMD), AVP Merck, Pfizer and AstraZeneca. Pharmaceutical physician executive with over 16 years of broad experience across multiple critical functions including clinical research and medical affairs, clinical operations, regulatory affairs, quality & compliance, pharmacovigilance, and portfolio & project management/leadership.

Michel Lamontagne, LL.L, ASC, C.Dir.

Expertise in financial, health and medical technology sectors. Experienced in startup, growth and governance of companies. Board member of Montreal CHUM hospital.

Nathan Yoganathan, Ph.D.

Founder and chief scientific officer at KalGene Pharmaceuticals. University and industrial research scientist.

Aman Badhwar, Ph.D.

Researcher at University of Montreal. Multimodal expertise in genomics, proteomics, metabolomics and imaging with a focus on neurodegenerative pathology. Expertise in neurovascular coupling and a general interest in the heart-brain link to neurodegeneration.

Contact Us